Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

K. Wenn*, L. Tomala, S. Wilop, L. Vankann, C. Hasenbank, O. Frank, A. Hochhaus, F. J. Giles, T. Lange, M. C. Müller, S. Koschmieder, F. Beier, P. Ziegler, T. H. Brümmendorf

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

11 Scopus citations
Original languageEnglish (US)
Pages (from-to)2402-2404
Number of pages3
Issue number12
StatePublished - Dec 1 2015

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this